Project

A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy

Automatically Closed · 2012 until 2013

Siano Marco, Früh Martin